Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01221181|
Recruitment Status : Unknown
Verified February 2014 by Gerald B. Appel, Columbia University.
Recruitment status was: Active, not recruiting
First Posted : October 14, 2010
Last Update Posted : February 7, 2014
This is an open label, non-blinded, proof of concept efficacy and safety study of eculizumab in patients with biopsy proven DDD or C3 nephropathy. The trial will consist of adult patients with these diseases who have > 1 gram of proteinuria or a decreased glomerular filtration rate (GFR), both predictors of a poor long-term outcome in many glomerular diseases. They will be treated with eculizumab for one year. The goals will be to determine whether treatment leads to an improvement in kidney function, defined by remissions of proteinuria and improvements in estimated GFR (measured by serum creatinine), and to improvement in histologic parameters, including percentage of non-affected glomeruli, interstitial fibrosis, intensity of C3 staining of immunofluorescence, and amount of electron dense deposits by electron microscopy.
All enrolled subjects will receive eculizumab treatment for one year. There will be 29 study visits over 53 weeks. The goal is to determine whether this treatment will improve kidney function, as evidenced by less protein in the urine and improved lab results.
An EXTENSION TREATMENT PHASE has been added. After completing the study, patients are followed with labs every four weeks as per standard of care. If labs suggest a relapse, they will be allowed to continue on therapy at the previous dosage until this drug receives FDA approval for this indication. Treatment intervals and dosage are identical to the original study.
|Condition or disease||Intervention/treatment||Phase|
|Dense Deposit Disease Membranoproliferative Glomerulonephritis||Drug: Eculizumab||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
Eculizumab 900 mg IV one a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
900 mg IV once a week x 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
Patients will be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitidis vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
Other Name: Eculizumab (Soliris®)
- Number of subjects with complete remission of proteinuria [ Time Frame: Up to 1 year after therapy ]The primary end point is complete remission, defined as remission of proteinuria to <500 mg/day with normal renal function.
- Change in proteinuria level [ Time Frame: Up to 1 year after therapy ]Partial remission, a secondary endpoint, will be defined as reduction in proteinuria by at least 50% and to <2 g/day with stable renal function (i.e. no more than a 20% increase in serum creatinine).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01221181
|United States, New York|
|Columbia University Medical Center, Glomerular Center|
|New York, New York, United States, 10032|
|Columbia University Medical Center, Nephrology Clinical Research Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Gerald B Appel, MD||Columbia University|